Profile data is unavailable for this security.
About the company
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
- Revenue in USD (TTM)35.33m
- Net income in USD-329.12m
- Incorporated2015
- Employees309.00
- LocationRelay Therapeutics Inc399 Binney Street, 2Nd FloorCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 370-8837
- Fax+1 (302) 655-5049
- Websitehttps://relaytx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Silence Therapeutics plc | 33.49m | -44.31m | 900.54m | 115.00 | -- | 5.77 | -- | 26.89 | -0.3894 | -0.3894 | 0.2843 | 1.13 | 0.1829 | -- | 5.37 | 291,211.50 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 926.72m | 267.00 | -- | -- | -- | 2.24 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 944.03m | 593.00 | -- | 16.65 | -- | 6.71 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 946.09m | 29.00 | -- | 10.85 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 949.80m | 586.00 | -- | 0.8394 | -- | 26.54 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 954.14m | 140.00 | -- | 3.60 | -- | 25.63 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 970.34m | 309.00 | -- | 1.30 | -- | 27.47 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Liquidia Corp | 15.97m | -107.69m | 988.39m | 136.00 | -- | 11.44 | -- | 61.90 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Innoviva Inc | 311.59m | 181.39m | 993.50m | 112.00 | 7.26 | 1.42 | 4.52 | 3.19 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 994.41m | 1.22k | -- | 0.9263 | -- | 4.76 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 999.04m | 296.00 | -- | 4.43 | -- | 9.39 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Pharvaris NV | 0.00 | -113.70m | 1.01bn | 82.00 | -- | 2.63 | -- | -- | -2.54 | -2.54 | 0.00 | 7.14 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.02bn | 46.00 | -- | 3.20 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -75.45m | 1.02bn | 49.00 | -- | 2.62 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.04bn | 197.00 | 15.43 | 4.68 | 4.33 | 1.83 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
Data as of Jun 14 2024. Currency figures normalised to Relay Therapeutics Inc's reporting currency: US Dollar USD
44.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 11.67m | 8.82% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.74m | 5.85% |
| Casdin Capital LLCas of 31 Mar 2024 | 7.42m | 5.61% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 6.69m | 5.06% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.02m | 4.55% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 5.93m | 4.48% |
| ArrowMark Colorado Holdings LLCas of 31 Mar 2024 | 4.01m | 3.03% |
| Braidwell LPas of 31 Mar 2024 | 3.74m | 2.83% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 3.10m | 2.34% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.07m | 2.32% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
